Guardant Health, Inc. (GH)

Cancer blood testing laboratory, one pattern. Read November 9, 2026 from the annual report for the period ending December 31, 2025, filed February 19, 2026. Ranked 53 of the 145 Healthcare companies read so far, by the share within reach now.

The filing states 2,506 employees at December 31, 2025, about 2,278 in the U.S., and describes one cancer testing business with no count by function, so the whole workforce is read at medical and diagnostic laboratories by description.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 34% now, 39% at the end of 2027, 41% at the end of 2028, 41% at the end of 2030. By the patterns, the work is about 41% desk work, 19% people work and 40% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 60% of the working time stays with people (conversation, in-person and hands-on work), 33% becomes checking a model's work and 6% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

2,506 employees as of December 31, 2025 (stated). Approximately 2,278 of 2,506 employees in the U.S., the rest in Asia, Europe and Canada (stated).

The filing: “As of December 31, 2025, we had 2,506 employees, 2,490 of which are full-time employees and approximately 2,278 of which are in the U.S., with the remainder in Asia, Europe and Canada.”

The workforce as industry patterns

What the filing says about the workforce: 2,506 employees at December 31, 2025, 2,490 full-time, about 2,278 in the U.S.; up from 1,999 a year earlier; independent contractors engaged to assist operations; about 51% racially or ethnically diverse and 53% female.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Medical and Diagnostic Laboratories, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.

• Labcorp Holdings Inc. (LH, 71,000 employees)35% now, 45% by 2028
• Quest Diagnostics Incorporated (DGX, 57,000 employees)34% now, 41% by 2028
• RadNet, Inc. (RDNT, 11,264 employees)34% now, 41% by 2028
• Natera, Inc. (NTRA, 6,140 employees)34% now, 41% by 2028
• Lumexa Imaging Holdings, Inc. Common Stock (LMRI, 5,019 employees)34% now, 41% by 2028
• Tempus AI, Inc. (TEM, 3,800 employees)39% now, 51% by 2028
• Myriad Genetics, Inc. (MYGN, 2,700 employees)34% now, 41% by 2028
• NeoGenomics, Inc. (NEO, 2,500 employees)34% now, 41% by 2028

What the filing says about AI

31 sentences in the filing name AI. The filing describes AI analytics in its blood and tissue tests, the GuardantINFORM in-silico research platform built with AI-enabled analytical tools for biopharmaceutical companies, and AI-powered PD-L1 analysis in its tissue test.

• “We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics.”
• “Using data collected from our tests and through AI-enabled analytical tools, we have also developed our GuardantINFORM platform to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.”
• “Guardant360 Tissue Test To complement our liquid biopsy-based products, we offer Guardant Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data, to provide researchers and cancer care teams with a more comprehensive view of cancer.”
• “This genomic and epigenetic data is first matched with clinically relevant information, and through AI-enabled analytical tools and expertise, unlocks important insights into disease progression and treatment impact that can be fed back into drug discovery and development, as well as clinical research and practice.”
• “Our competitors within the liquid biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences Corporation; BillionToOne, Inc.; Quest Diagnostics, Inc.; and Laboratory Corporation of America.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20215median 0
• Fiscal 20223median 0
• Fiscal 20233median 1
• Fiscal 202411median 4
• Fiscal 202531median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The Index row carries the 2,490 full-time count; the filing states 2,506 employees in all (rule 2).
• Independent contractors assisting operations are not counted (rule 8).
• No count by function; the research and biopharma data staff are inside the laboratory pattern (c).

Source: the company's annual report on EDGAR, accession 0001576280-26-000013, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.